{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T16:58:31Z","timestamp":1648832311867},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T00:00:00Z","timestamp":1479686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T00:00:00Z","timestamp":1479686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1038\/bmt.2016.292","type":"journal-article","created":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T14:47:02Z","timestamp":1479739622000},"page":"199-200","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diffuse large B-cell lymphoma: the challenge of relapse after an autologous stem cell transplant"],"prefix":"10.1038","volume":"52","author":[{"given":"S P","family":"Robinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,21]]},"reference":[{"key":"BFbmt2016292_CR1","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","volume":"23","author":"LH Sehn","year":"2005","unstructured":"Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027\u20135033.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016292_CR2","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540\u20131545.","journal-title":"N Engl J Med"},{"key":"BFbmt2016292_CR3","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","volume":"30","author":"C Gisselbrecht","year":"2012","unstructured":"Gisselbrecht C, Schmitz N, Mounier N, Gingh Gill D, Linch D, Trneny M et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. J Clin Oncol 2012; 30: 4462\u20134469.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016292_CR4","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 2014; 32: 3490\u20133496.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016292_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/bmt.2015.286","volume":"51","author":"SP Robinson","year":"2016","unstructured":"Robinson SP, Boumendil A, Finel H, Blaise D, Poir\u00e9 X, Nicolas-Virelizier E et al. Autologous stem cell transplantation for relapsed\/refractory diffuse large B-cell lymphoma: efficacy in the Rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party. Bone Marrow Transplant 2016; 51: 365\u2013371.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016292_CR6","doi-asserted-by":"crossref","unstructured":"Van Den Neste E, Schmitz N, Mournier N, Gill D, Linch D, Trneny M et al. Outcomes of diffuse large B-cell lymphoma relapsing after autologous stem cell transplantation (ASCT): an analysis of patients included in the CORAL study. Bone Marrow Transplant (e-pub ahead of print 19 September 2016; doi:10.1038\/bmt.2016.213).","DOI":"10.1038\/bmt.2016.213"},{"key":"BFbmt2016292_CR7","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","volume":"29","author":"RJW van Kampen","year":"2011","unstructured":"van Kampen RJW, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant J-P et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29: 1342\u20131348.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016292_CR8","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","volume":"27","author":"KJ Thomson","year":"2009","unstructured":"Thomson KJ, Morris EC, Bloor A, Cook G, Milligan D, Parker A et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 426\u2013432.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016292_CR9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1200\/JCO.2007.15.8865","volume":"27","author":"CA Rodrigues","year":"2009","unstructured":"Rodrigues CA, Sanz G, Brunstein CG, Sanz J, Wagner JE, Renaud M et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2009; 27: 256\u2013263.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016292_CR10","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","volume":"34","author":"N Ghosh","year":"2016","unstructured":"Ghosh N, Karmali R, Rocha V . Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research analysis. J Clin Oncol 2016; 34: 3141\u20133149.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016292_CR11","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1038\/leu.2016.125","volume":"30","author":"S Dietrich","year":"2016","unstructured":"Dietrich S, Finel H, Martinez C, Tischer J, Blaise D, Chevallier P et al. Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European Society for Blood and Marrow Transplantation. Leukemia 2016; 30: 2086\u20132089.","journal-title":"Leukemia"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2016292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016292","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:06:39Z","timestamp":1648062399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2016292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,21]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["BFbmt2016292"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2016.292","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,21]]},"assertion":[{"value":"4 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}